VYCOR MEDICAL, INC.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $406.3K | $337.0K | $308.2K | $308.6K | $482.8K | $361.0K | $271.3K | $310.0K |
| Cost of Revenue | $35.2K | $37.0K | $42.0K | $32.3K | $39.8K | $30.8K | $37.2K | $42.2K |
| Gross Profit | $371.1K | $300.0K | $266.2K | $276.3K | $443.0K | $330.2K | $234.1K | $267.8K |
| Gross Margin | 91.3% | 89.0% | 86.4% | 89.5% | 91.8% | 91.5% | 86.3% | 86.4% |
| Operating Expenses | ||||||||
| Research & Development | $2.3K | — | $2.3K | $7.3K | $7.6K | $5.5K | — | — |
| SG&A Expense | $337.8K | $294.6K | $313.7K | $280.1K | $324.5K | $277.1K | $310.9K | $341.3K |
| Operating Income | $16.2K | $-9.5K | $-64.1K | $-25.5K | $96.5K | $33.2K | $-91.2K | $-88.0K |
| Operating Margin | 4.0% | -2.8% | -20.8% | -8.3% | 20.0% | 9.2% | -33.6% | -28.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-10.0K | $-30.5K | $-90.0K | $-51.5K | $70.8K | $7.6K | $-115.9K | $-112.3K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-10.0K | $-30.6K | $-93.1K | $-51.9K | $68.4K | $6.9K | $-116.5K | $-114.8K |
| Net Margin | -2.5% | -9.1% | -30.2% | -16.8% | 14.2% | 1.9% | -43.0% | -37.0% |
| EPS (Basic) | $0.00 | $-0.01 | $0.00 | $-0.01 | $0.00 | $0.00 | $0.00 | $-0.01 |
| EPS (Diluted) | $0.00 | $-0.01 | $0.00 | $-0.01 | $0.00 | $0.00 | — | $-0.01 |
| Shares Outstanding (Basic) | 32.6M | 32.6M | 32.6M | 32.6M | 32.6M | 32.5M | 31.7M | 32.0M |
| Shares Outstanding (Diluted) | 32.6M | 32.6M | 32.6M | 32.6M | 37.5M | 32.5M | 31.7M | 32.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |